We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $472M
1-Year Est. Return 106.83%
This Fund
S&P 500
This Quarter Est. Return
+24.83%
1 Year Est. Return
+106.83%
3 Year Est. Return
+792.82%
5 Year Est. Return
+1,009.42%
10 Year Est. Return
AUM
$360M
AUM Growth
+$71.2M
Cap. Flow
+$5.62M
Cap. Flow %
1.56%
Top 10 Hldgs %
99.63%
Holding
13
New
Increased
2
Reduced
Closed

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$3.21M
2
BMEA icon
Biomea Fusion
BMEA
+$2.41M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$13.4B
$262M 72.85%
6,068,125
VRNA
2
DELISTED
Verona Pharma
VRNA
$58.2M 16.18%
615,352
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.62B
$12.3M 3.43%
1,316,806
+291,806
+28% +$3.21M
GLUE icon
4
Monte Rosa Therapeutics
GLUE
$1.11B
$6.64M 1.85%
1,472,331
BCAX
5
Bicara Therapeutics
BCAX
$1.5B
$5.29M 1.47%
568,919
NUVB icon
6
Nuvation Bio
NUVB
$2.04B
$4.95M 1.38%
2,541,009
BMEA icon
7
Biomea Fusion
BMEA
$130M
$3.69M 1.03%
2,048,757
+1,250,000
+156% +$2.41M
CMPS
8
Compass Pathways
CMPS
$1.91B
$3.36M 0.93%
1,198,418
ELEV
9
DELISTED
Elevation Oncology
ELEV
$1.04M 0.29%
2,834,910
CALC icon
10
CalciMedica
CALC
$13.5M
$834K 0.23%
104,223
ACRS icon
11
Aclaris Therapeutics
ACRS
$813M
$617K 0.17%
434,455
MRKR icon
12
Marker Therapeutics
MRKR
$19.5M
$498K 0.14%
325,370
OKUR
13
OnKure Therapeutics
OKUR
$119M
$212K 0.06%
88,607

Similar funds

Aisling Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Aisling Capital Management held 13 positions worth $360M, up 25% from $288M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2025: portfolio turnover was 0%. Aisling Capital Management opened no new positions and made no exits, leaving the 13-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management added most to Syndax Pharmaceuticals in Q2 2025, an estimated $3.21M increase.
  • Aisling Capital Management's ten largest holdings make up 100% of its $360M portfolio in Q2 2025.
  • Aisling Capital Management opened 0 new positions and closed 0 in Q2 2025.
  • Aisling Capital Management's portfolio value rose 25% quarter-over-quarter to $360M.

Based on Aisling Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.